Mads Høgholen, Director of Finance & Operations at CEPI said: “CEPI was established in 2017 and has grown quickly to support a varied portfolio of vaccine development projects against emerging infectious diseases. As the work of the organization expands, it is essential that we have the right business systems in place to enable us to work as efficiently and effectively as possible. Our collaboration with Isobar and Salesforce will help us navigate the business transformation process, and we are looking forward to benefiting from their experience and professionalism as we implement this project.”
Patrik Gamryd, CEO at Isobar Switzerland said: “CEPI has become one of the leading actors working on COVID-19 vaccine development. In these intense and demanding times, it is especially important to keep up with business transformation. We are proud to be acting as an extended team and supporting CEPI to become stronger and gain efficiency despite the COVID-19 crisis. Together with our technology partner Salesforce we are able to help this important organization to make an impact.”
Stephane Viallet, Vice President, Global Agency Alliances at Salesforce said: “We are excited to see CEPI innovate using Salesforce to implement an agile, purpose-built platform to help streamline funding that will support the development of vaccines against emerging infectious diseases, including COVID-19. We’re excited to see global digital agencies such as our partner Isobar designing and implementing new experiences that leverage the power of Salesforce. This is an example of how the Salesforce ecosystem can come together to drive impact during this challenging time.”
Salesforce and others are among the trademarks of salesforce.com, inc.
Press contact: Margherita Masiello I firstname.lastname@example.org | +41 78 235 66 6
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated nine partnerships to develop vaccines against the novel coronavirus. The programmes will leverage rapid response platforms already supported by CEPI as well as new partnerships. The aim is to advance COVID-19 vaccine candidates into clinical testing as quickly as possible. Before the emergence of COVID-19 CEPI’s priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).